There are several different TKIs that are Food and Drug Administration (FDA) approved for the treatment of CML, which is often dependent on STAT5 signalling, such as imatinib that inhibits Bcr-Abl, dasatinib and nilotinib [118,119]. The gene discussed is STAT5B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.